UNSPSC 51111634: Emitefur

This classification denotes a pyrimidine antagonist with the molecular formula C28H19FN4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I50NF4AQ2, chemically known as m-((3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2h)-pyrimidinyl)carbonyl)benzoic acid, 2-ester with 2,6-dihydroxynicotinonitrile, benzoate but generally known as emitefur, which bears US NIH Compound Identifier 65910. European Medicines Agency schedules Emitefur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06508MIG.

UNSPSC 51111634 Emitefur is a Commodity code under which state and local health agencies solicit pharmaceutical products and related supply-chain services, specifically direct-to-manufacturer prescription fulfillment arrangements that bypass traditional pharmacy benefit managers and wholesalers. The code captures state health department acquisitions of prescription medications and ancillary pharmacy services tied to alternative contracting and distribution models—in this case, direct negotiation between state health plans and pharmaceutical manufacturers to manage cost and improve fulfillment efficiency. Issuing bodies include state health and human services commissions acting on behalf of employee health plans and Medicaid programs.

Texas Health and Human Services Commission posted RFI No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI solicits information from vendors about experience with direct contracting for self-insured employers and government health plans, flexibility to negotiate net-pricing models without rebates, and capacity to implement value-based or outcomes-based agreements. The solicitation represents exploratory market intelligence gathering rather than a binding competitive award; the state indicated intent to use vendor responses to inform detailed specifications and pricing models for a subsequent formal RFP. No award value, budget range, or set-aside designations are specified in the RFI materials at this preliminary stage.